Skip to main content

Hyseq Losses Dwindle, Revenues Climb for Q2

NEW YORK, July 25-Hyseq today reported a small decrease in net losses and a modest increase in revenues for the second quarter of 2002.


For the three months ended June 30, 2002, Hyseq reported a net loss of $8.1 million, or $0.37 per share. Losses for the second quarter 2001 were $8.4 million, or $0.55 per share.


Hyseq said that its revenues for the quarter had climbed to $11.9 million from $11.6 million for the equivalent quarter in 2001.


During the second quarter of 2002, the company also pocketed about $15 million from a private stock placement.


R&D expenditures dwindled slightly, from $11 million in the second quarter of 2001 to $10.7 million in Q2 2002.


Hyseq said it had $11.8 million in cash on hand as of June 30, 2002.


For more information, see the company quarterly report.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.